vs
Ginkgo Bioworks Holdings, Inc.（DNA）与TELOS CORP（TLS）财务数据对比。点击上方公司名可切换其他公司
TELOS CORP的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.4倍（$46.8M vs $33.4M），TELOS CORP同比增速更快（77.4% vs -23.8%），TELOS CORP自由现金流更多（$8.0M vs $-47.7M），过去两年TELOS CORP的营收复合增速更高（25.7% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
泰洛斯公司（Telos Corporation）是一家信息技术与网络安全企业，总部位于美国弗吉尼亚州阿什本。公司主要服务对象为政府与企业客户，业务合同大部分来自美国国防部，核心客户涵盖美国军方、情报机构、民政部门以及北约盟友机构。
DNA vs TLS — 直观对比
营收规模更大
TLS
是对方的1.4倍
$33.4M
营收增速更快
TLS
高出101.2%
-23.8%
自由现金流更多
TLS
多$55.6M
$-47.7M
两年增速更快
TLS
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $46.8M |
| 净利润 | — | $-16.3M |
| 毛利率 | — | 35.0% |
| 营业利润率 | -211.9% | -39.6% |
| 净利率 | — | -34.9% |
| 营收同比 | -23.8% | 77.4% |
| 净利润同比 | — | -74.8% |
| 每股收益（稀释后） | $-1.41 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNATLS
| Q4 25 | $33.4M | $46.8M | ||
| Q3 25 | $38.8M | $51.4M | ||
| Q2 25 | $49.6M | $36.0M | ||
| Q1 25 | $48.3M | $30.6M | ||
| Q4 24 | $43.8M | $26.4M | ||
| Q3 24 | $89.0M | $23.8M | ||
| Q2 24 | $56.2M | $28.5M | ||
| Q1 24 | $37.9M | $29.6M |
净利润DNATLS
| Q4 25 | — | $-16.3M | ||
| Q3 25 | $-80.8M | $-2.1M | ||
| Q2 25 | $-60.3M | $-9.5M | ||
| Q1 25 | $-91.0M | $-8.6M | ||
| Q4 24 | — | $-9.3M | ||
| Q3 24 | $-56.4M | $-28.1M | ||
| Q2 24 | $-217.2M | $-7.8M | ||
| Q1 24 | $-165.9M | $-7.4M |
毛利率DNATLS
| Q4 25 | — | 35.0% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | — | 33.2% | ||
| Q1 25 | — | 39.8% | ||
| Q4 24 | — | 40.3% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 34.1% | ||
| Q1 24 | — | 37.0% |
营业利润率DNATLS
| Q4 25 | -211.9% | -39.6% | ||
| Q3 25 | -231.8% | -4.8% | ||
| Q2 25 | -132.1% | -27.5% | ||
| Q1 25 | -184.1% | -29.5% | ||
| Q4 24 | -236.3% | -37.6% | ||
| Q3 24 | -62.0% | -121.4% | ||
| Q2 24 | -396.7% | -30.3% | ||
| Q1 24 | -469.1% | -28.5% |
净利率DNATLS
| Q4 25 | — | -34.9% | ||
| Q3 25 | -207.9% | -4.1% | ||
| Q2 25 | -121.6% | -26.5% | ||
| Q1 25 | -188.2% | -28.1% | ||
| Q4 24 | — | -35.4% | ||
| Q3 24 | -63.3% | -118.0% | ||
| Q2 24 | -386.4% | -27.2% | ||
| Q1 24 | -437.3% | -24.9% |
每股收益（稀释后）DNATLS
| Q4 25 | $-1.41 | $-0.22 | ||
| Q3 25 | $-1.45 | $-0.03 | ||
| Q2 25 | $-1.10 | $-0.13 | ||
| Q1 25 | $-1.68 | $-0.12 | ||
| Q4 24 | $-1.91 | $-0.13 | ||
| Q3 24 | $-1.08 | $-0.39 | ||
| Q2 24 | $-4.23 | $-0.11 | ||
| Q1 24 | $-3.32 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $53.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $96.0M |
| 总资产 | $1.1B | $139.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNATLS
| Q4 25 | $422.6M | $53.2M | ||
| Q3 25 | $495.5M | $59.0M | ||
| Q2 25 | $559.4M | $57.0M | ||
| Q1 25 | $325.3M | $57.8M | ||
| Q4 24 | $561.6M | $54.6M | ||
| Q3 24 | $616.2M | $69.8M | ||
| Q2 24 | $730.4M | $80.1M | ||
| Q1 24 | $840.4M | $93.9M |
股东权益DNATLS
| Q4 25 | $508.6M | $96.0M | ||
| Q3 25 | $559.8M | $119.7M | ||
| Q2 25 | $613.0M | $118.4M | ||
| Q1 25 | $647.4M | $126.1M | ||
| Q4 24 | $716.1M | $127.1M | ||
| Q3 24 | $797.9M | $129.5M | ||
| Q2 24 | $833.1M | $149.1M | ||
| Q1 24 | $987.3M | $154.4M |
总资产DNATLS
| Q4 25 | $1.1B | $139.9M | ||
| Q3 25 | $1.2B | $164.3M | ||
| Q2 25 | $1.2B | $165.0M | ||
| Q1 25 | $1.3B | $158.1M | ||
| Q4 24 | $1.4B | $158.2M | ||
| Q3 24 | $1.5B | $166.3M | ||
| Q2 24 | $1.6B | $182.4M | ||
| Q1 24 | $1.6B | $195.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $8.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $8.0M |
| 自由现金流率自由现金流/营收 | -142.8% | 17.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $29.4M |
8季度趋势，按日历期对齐
经营现金流DNATLS
| Q4 25 | $-47.7M | $8.0M | ||
| Q3 25 | $-31.6M | $9.1M | ||
| Q2 25 | $-40.3M | $7.0M | ||
| Q1 25 | $-51.5M | $6.1M | ||
| Q4 24 | $-42.4M | $-10.5M | ||
| Q3 24 | $-103.5M | $-7.1M | ||
| Q2 24 | $-84.4M | $-8.0M | ||
| Q1 24 | $-89.3M | $-350.0K |
自由现金流DNATLS
| Q4 25 | $-47.7M | $8.0M | ||
| Q3 25 | — | $8.7M | ||
| Q2 25 | $-40.3M | $6.8M | ||
| Q1 25 | $-59.1M | $6.0M | ||
| Q4 24 | $-56.1M | $-12.4M | ||
| Q3 24 | $-118.6M | $-7.1M | ||
| Q2 24 | $-111.4M | $-8.2M | ||
| Q1 24 | $-96.0M | $-447.0K |
自由现金流率DNATLS
| Q4 25 | -142.8% | 17.0% | ||
| Q3 25 | — | 16.9% | ||
| Q2 25 | -81.2% | 19.0% | ||
| Q1 25 | -122.4% | 19.5% | ||
| Q4 24 | -128.0% | -47.0% | ||
| Q3 24 | -133.2% | -30.0% | ||
| Q2 24 | -198.2% | -28.9% | ||
| Q1 24 | -252.9% | -1.5% |
资本支出强度DNATLS
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.1% | 0.4% | ||
| Q1 25 | 15.8% | 0.4% | ||
| Q4 24 | 31.3% | 7.1% | ||
| Q3 24 | 16.9% | 0.2% | ||
| Q2 24 | 48.1% | 0.8% | ||
| Q1 24 | 17.7% | 0.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
TLS
| Security Solutions Segment | $44.8M | 96% |
| Secure Networks Segment | $1.9M | 4% |
